NCT00424086 - Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

January 31, 2007

Study Completion Date

September 30, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

Inactivated seasonal influenza vaccine (split virus, vero cell derived)

BIOLOGICAL

Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]

Trial Locations (8)

1090

Universitaetsklinik f. Klinische Pharmakologie, Allgemeines Krankenhaus Wien (University Hospital for Clinical Pharmacology, General Hospital of Vienna), Vienna

8042

Kinemed, Graz

22769

MDS Pharma Services Germany GmbH, Hamburg

55116

Internistische Gemeinschaftspraxis Dr. Regner & Dr. Schmitt (Group practice for internal medicine), Mainz

80636

Harrison Clinical Research, Munich

31-135

"Zespol Przychodni Specjalistycznych DIAB-END-COR Sp. z o.o.", Krakow

10-461

PANTAMED Sp. z o.o., Olsztyn

22-400

Niepubliczny Zaklad Opieki Zdrowotnej, Osrodek Zdrowia w Lipsku, Zamość

All Listed Sponsors

lead

Alachua Government Services, Inc.

INDUSTRY